Tirzepatide
A dual GIP and GLP-1 receptor agonist with strong effects on appetite, glucose handling, and body composition.
Overview
Tirzepatide is the first dual-action incretin agonist, simultaneously activating both GIP and GLP-1 receptors. This dual mechanism has produced some of the most significant weight loss outcomes in modern peptide research.
Benefits
- Reduces appetite and caloric intake
- Improves insulin sensitivity beyond single-agonist therapies
- Supports significant lean and fat-mass changes
- Once-weekly dosing schedule
Mechanism of Action
Tirzepatide simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. This dual action enhances insulin response, suppresses glucagon, slows gastric emptying, and modulates appetite centers in the brain.
Dosage (informational only)
- Typical range
- 2.5–15 mg per week
- Frequency
- Weekly subcutaneous administration
Titration is typically slow to mitigate gastrointestinal effects. Use only under clinical supervision.
Side Effects
- Nausea and vomiting
- Diarrhea or constipation
- Decreased appetite
- Injection site reactions
Related peptides
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing some of the largest weight-loss results recorded in trials.
A small-molecule oral GLP-1 receptor agonist studied as a needle-free alternative to injectable incretin therapy.